Medium-term zom stock forecast simulations point towards a gradual climb as industry consolidation improves competitive positioning. In a little over two months, shares have soared in value more than threefold. Even so, another many-fold move higher may not be out of the question. Reaching 10x from its current price may be somewhat of a stretch goal, yet another two or threefold run is certainly nothing to sneeze at. Consider shares worthy of a speculative buy at current prices. If Barfresh sells off after this recent rally, consider it an even stronger opportunity among high-risk stocks. If Zomedica can successfully commercialize Truforma, the stock could be a good buy. However, like all companies in the pre-revenue stage, it's still a high-risk bet. In markets, risk and return tend to go hand in hand. Market sentiment is mixed, as investors weigh pandemic recovery-driven growth against competitive pressures in the food delivery sector. Analysts are monitoring quarterly revenue trends closely.